018390094

IZEPLIFY

---

February 3, 2021

Trademark Summary

The trademark application IZEPLIFY was filed by Eli Lilly and Company, a U.S. corporation (the "Applicant"). The application was published for oppositions on April 25, 2021, and it was registered by office on August 2, 2021 without any oppositions.

The application was filed in English (German was selected as the second language).

---

Goods And Services

• The mark was filed in class 5 with following description of goods:
  
  1. Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, diagnosis and prevention of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders
  2. Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, diagnosis and prevention of fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders
  3. Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, diagnosis and prevention of migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases
  4. Diagnostic agents, preparations and substances for medical purposes
  5. Diagnostic scanning agents for medical use, namely, diagnostic scanning agents for in vivo use
  6. Radiopharmaceutical diagnostic preparations for medical use
  7. Radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative amyloid diseases
  8. Pharmaceutical preparations.